Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on blood pressure and the kidney

Veltmar, 1991, From tissue angiotensin converting enzyme inhibition to antihypertensive effect, Am J Hypertens, 4, 263S, 10.1093/ajh/4.3.263S Weir, 1999, The renin-angiotensin-aldosterone system, Am J Hypertens, 12, 205S, 10.1016/S0895-7061(99)00103-X Border, 1998, Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis, Hypertension, 31, 181, 10.1161/01.HYP.31.1.181 Vaughan, 1995, Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis, J Clin Invest, 95, 995, 10.1172/JCI117809 Hostetter, 2001, Aldosterone in progressive renal disease, Semin Nephrol, 21, 573, 10.1053/snep.2001.26797 Siragy, 2000, The role of the AT2 receptor in hypertension, Am J Hypertens, 13, 62S, 10.1016/S0895-7061(00)00274-0 Dzau, 1991, Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia, Hypertension, 18, 100, 10.1161/01.HYP.18.4_Suppl.II100 Arima, 1997, Possible role of p-450 metabolite of arachidonic acid in vasodilator mechanism of angiotensin II type 2 receptor in the isolated microperfused rabbit afferent arteriole, J Clin Invest, 100, 2816, 10.1172/JCI119829 Ichiki, 1995, Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor, Nature, 377, 748, 10.1038/377748a0 Tsuzuki, 1996, Angiotensin II type 2 receptor inhibits cell proliferation and activates tyrosine phosphatase, Hypertension, 28, 916, 10.1161/01.HYP.28.5.916 Mooser, 1990, Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition, J Cardiovasc Pharmacol, 15, 276, 10.1097/00005344-199002000-00015 Juillerat, 1990, Determinants of angiotensin II generation during converting enzyme inhibition, Hypertension, 16, 564, 10.1161/01.HYP.16.5.564 Cervenka, 2001, Angiotensin II-induced hypertension in bradykinin b2 receptor knockout mice, Hypertension, 37, 967, 10.1161/01.HYP.37.3.967 Hutchison, 1995, The antiproteinuric action of angiotensin-converting enzyme is dependent on kinin, J Am Soc Nephrol, 6, 1216, 10.1681/ASN.V641216 Vaughan, 1997, The renin-angiotensin system and fibrinolysis, Am J Cardiol, 79, 12, 10.1016/S0002-9149(97)00124-0 Guazzi, 1998, Antihypertensive efficacy of angiotensin converting enzyme inhibition and aspirin counteraction, Clin Pharmacol Ther, 63, 79, 10.1016/S0009-9236(98)90123-0 Materson, 1993, Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo, N Engl J Med, 328, 914, 10.1056/NEJM199304013281303 1987, Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS), N Engl J Med, 316, 1429, 10.1056/NEJM198706043162301 1993, Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure, Lancet, 342, 821 Yusuf, 2000, Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators, N Engl J Med, 342, 145, 10.1056/NEJM200001203420301 Buhler, 1984, Renin profiling to select antihypertensive baseline drugs. Renin inhibitors for high-renin and calcium entry blockers for low-renin patients, Am J Med, 77, 36 Townsend, 1990, Combination of converting enzyme inhibitor with diuretic for the treatment of hypertension, Arch Intern Med, 150, 1175, 10.1001/archinte.1990.00390180019003 Holland, 1983, Synergistic effect of captopril with hydrochlorothiazide for the treatment of low-renin hypertensive black patients, Hypertension, 5, 235, 10.1161/01.HYP.5.2.235 Bakris, 2000, Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine, Arch Intern Med, 160, 685, 10.1001/archinte.160.5.685 Maschio, 1996, Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency, N Engl J Med, 334, 939, 10.1056/NEJM199604113341502 Ruggenenti, 1997, Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN), Kidney Int Suppl, 63, S54 Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet. 1997;349:1857–1863 Lewis, 1993, The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy, N Engl J Med, 329, 1456, 10.1056/NEJM199311113292004 Brenner, 2001, Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, N Engl J Med, 345, 861, 10.1056/NEJMoa011161 Lewis, 2001, Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes, N Engl J Med, 345, 851, 10.1056/NEJMoa011303 Palla, 1994, Effect of increasing doses of lisinopril on proteinuria of normotensive patients with IGA nephropathy and normal renal function, Int J Clin Pharmacol Res, 14, 35 Peters, 1998, Targeting TGF-beta overexpression in renal disease, Kidney Int, 54, 1570, 10.1046/j.1523-1755.1998.00164.x Remuzzi, 1998, Pathophysiology of progressive nephropathies, N Engl J Med, 339, 1448, 10.1056/NEJM199811123392007 Viberti, 1994, Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria, JAMA, 271, 275, 10.1001/jama.1994.03510280037029 1996, Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria, Diabetologia, 39, 587, 10.1007/BF00403306 Wilmer, 1999, Remission of nephrotic syndrome in type 1 diabetes, Am J Kidney Dis, 34, 308, 10.1016/S0272-6386(99)70360-4 Lewis, 1999, Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy, Am J Kidney Dis, 34, 809, 10.1016/S0272-6386(99)70036-3 Bakris, 1990, Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus, Ann Intern Med, 112, 707, 10.7326/0003-4819-112-9-707 Ritz, 1999, Nephropathy in patients with type 2 diabetes mellitus, N Engl J Med, 341, 1127, 10.1056/NEJM199910073411506 Ravid, 1993, Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients, Ann Intern Med, 118, 577, 10.7326/0003-4819-118-8-199304150-00001 Kagami, 1994, Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells, J Clin Invest, 93, 2431, 10.1172/JCI117251 Sano, 1994, Effects of long-term enalapril treatment on persistent micro-albuminuria in well-controlled hypertensive and normotensive NIDDM patients, Diabetes Care, 17, 420, 10.2337/diacare.17.5.420 Sano, 1996, Effects of long-term enalapril treatment on persistent microalbuminuria in normotensive type 2 diabetic patients, Diabetes Med, 13, 120, 10.1002/(SICI)1096-9136(199602)13:2<120::AID-DIA6>3.0.CO;2-F Trevisan, 1995, Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients, Am J Hypertens, 8, 876, 10.1016/0895-7061(95)00162-I Lebovitz, 1994, Renal protective effects of enalapril in hypertensive NIDDM, Kidney Int Suppl, 45, S150 Ravid, 1998, Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial, Ann Intern Med, 128, 982, 10.7326/0003-4819-128-12_Part_1-199806150-00004 Yokoyama, 1997, Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients, Diabetologia, 40, 405, 10.1007/s001250050694 2000, Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy, Lancet, 355, 253, 10.1016/S0140-6736(99)12323-7 Estacio, 1998, The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension, N Engl J Med, 338, 645, 10.1056/NEJM199803053381003 Hansson, 1999, Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension, Lancet, 353, 611, 10.1016/S0140-6736(98)05012-0 Tatti, 1998, Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM, Diabetes Care, 21, 597, 10.2337/diacare.21.4.597 Apperloo, 1991, Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease, BMJ, 303, 821, 10.1136/bmj.303.6806.821 Gansevoort, 1995, Antiproteinuric effect of blood-pressure-lowering agents, Nephrol Dial Transplant, 10, 1963 Peterson, 1995, Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study, Ann Intern Med, 123, 754, 10.7326/0003-4819-123-10-199511150-00003 Woo, 2000, ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IGA nephritis, Kidney Int, 58, 2485, 10.1046/j.1523-1755.2000.00432.x Morelli, 1990, Effects of converting-enzyme inhibition on barrier function in diabetic glomerulopathy, Diabetes, 39, 76, 10.2337/diacare.39.1.76 Agodoa, 2001, Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis, JAMA, 285, 2719, 10.1001/jama.285.21.2719 Jafar, 2001, The effect of angiotensin-converting-enzyme inhibitors on the progression of non-diabetic renal disease, Ann Intern Med, 135, 73, 10.7326/0003-4819-135-2-200107170-00007 Schrier, 2001, The effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease, Ann Intern Med, 135, 138, 10.7326/0003-4819-135-2-200107170-00015 Schrier, 2002, Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes, Kidney Int, 61, 1086, 10.1046/j.1523-1755.2002.00213.x Estacio, 2000, Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes, Diabetes Care, 23, B54 Mimran, 1999, Angiotensin receptor blockers: pharmacology and clinical significance, J Am Soc Nephrol, 10, S273 Campbell, 1995, Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme, J Cardiovasc Pharmacol, 26, 233, 10.1097/00005344-199508000-00009 Tsutsumi, 1999, Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation, J Clin Invest, 104, 925, 10.1172/JCI7886 Israili, 1992, Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology, Ann Intern Med, 117, 234, 10.7326/0003-4819-117-3-234 Pitt, 1997, Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan In The Elderly Study, ELITE), Lancet, 349, 747, 10.1016/S0140-6736(97)01187-2 Pitt, 2000, Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure, Lancet, 355, 1582, 10.1016/S0140-6736(00)02213-3 Willenheimer, 1999, AT1-receptor blockers in hypertension and heart failure, Eur Heart J, 20, 997, 10.1053/euhj.1999.1547 Soffer, 1995, Effects of losartan on a background of hydrochlorothiazide in patients with hypertension, Hypertension, 26, 112, 10.1161/01.HYP.26.1.112 Stergiou, 2001, Does the antihypertensive response to angiotensin converting enzyme inhibition predict the antihypertensive response to angiotensin receptor antagonism?, Am J Hypertens, 14, 688, 10.1016/S0895-7061(01)01307-3 Gansevoort, 1994, Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?, Kidney Int, 45, 861, 10.1038/ki.1994.113 Parving, 2001, The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes, N Engl J Med, 345, 870, 10.1056/NEJMoa011489 Zoccali, 1997, Antiproteinuric effect of losartan in patients with chronic renal diseases, Nephrol Dial Transplant, 12, 234, 10.1093/oxfordjournals.ndt.a027738 Mogensen, 2000, Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes, BMJ, 321, 1440, 10.1136/bmj.321.7274.1440 Russo, 1999, Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IGA nephropathy, Am J Kidney Dis, 33, 851, 10.1016/S0272-6386(99)70416-6 Russo, 2001, Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IGA nephropathy, Am J Kidney Dis, 38, 18, 10.1053/ajkd.2001.25176 Agarwal, 2001, Add-on angiotensin receptor blockade with maximized ACE inhibition, Kidney Int, 59, 2282, 10.1046/j.1523-1755.2001.00745.x Ruilope, 2000, Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease, J Hypertens, 18, 89, 10.1097/00004872-200018010-00013 Rossing, 2002, Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study, Diabetes Care, 25, 95, 10.2337/diacare.25.1.95 Agarwal, 2002, Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels, Am J Kidney Dis, 39, 486, 10.1053/ajkd.2002.31392 Kincaid-Smith, 2002, Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria, Nephrol Dial Transplant, 17, 597, 10.1093/ndt/17.4.597 Jacobsen, 2002, Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy, Nephrol Dial Transplant, 17, 1019, 10.1093/ndt/17.6.1019 Luño, 2002, Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies, Kidney Int, 62, 47, 10.1046/j.1523-1755.62.s82.10.x Peters, 1999, Dosing angiotensin II blockers—beyond blood pressure, Nephrol Dial Transplant, 14, 2568, 10.1093/ndt/14.11.2568 Nakao, 2003, Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE), Lancet, 361, 117, 10.1016/S0140-6736(03)12229-5